Literature DB >> 8562235

Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy.

C Seiler1, R Jenni, G Vassalli, M Turina, O M Hess.   

Abstract

BACKGROUND: To determine the incidence and prognosis of left ventricular dilatation and systolic dysfunction in 139 patients with hypertrophic cardiomyopathy during long term follow up.
METHODS: Left ventricular chamber dilatation and systolic dysfunction (both together referred to as left ventricular chamber dilatation) were determined echocardiographically. Chamber dilatation was defined as an increase in the left ventricular end diastolic diameter of > 2% per year combined with a decrease in midventricular systolic fractional shortening of > 2% per year of follow up [10.3 (SD 6) years]. The predictive value for left ventricular chamber dilatation of clinical, invasive, and echocardiographic variables and its prognosis were assessed.
RESULTS: In 119 of 139 individuals (86%), left ventricular chamber size and systolic function remained stable (group 1), and in 20/139 patients (14%) left ventricular chamber dilatation occurred during follow up (group 2). At baseline examination, symptoms such as dyspnoea and syncope occurred less often in group 1 than in group 2; New York Heart Association classification was lower in group 1 than in group 2 (P = 0.001). Left ventricular mass index relative to sex specific normal values was increased by 18% in group 1 and by 41% in group 2 (P = 0.04). Cumulative survival rates were slightly although not significantly higher in group 1 than in group 2. Event-free survival was significantly higher in group 1 than in group 2 (P < 0.05).
CONCLUSIONS: (1) The development of left ventricular chamber dilatation and systolic dysfunction in hypertrophic cardiomyopathy occurs in approximately 1.5% of the patients per year. (2) Factors associated with left ventricular dilatation are dyspnoea, syncope, a higher functional classification, and a higher degree of left ventricular hypertrophy. (3) Patients with chamber dilatation have a worse prognosis than those without, particularly regarding quality of life.

Entities:  

Mesh:

Year:  1995        PMID: 8562235      PMCID: PMC484070          DOI: 10.1136/hrt.74.5.508

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  24 in total

1.  Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy.

Authors:  C Yutani; M Imakita; H Ishibashi-Ueda; K Hatanaka; S Nagata; H Sakakibara; Y Nimura
Journal:  Am Heart J       Date:  1985-03       Impact factor: 4.749

2.  The analysis and presentation of surgical results by actuarial methods.

Authors:  R P Anderson; L I Bonchek; G L Grunkemeier; L E Lambert; A Starr
Journal:  J Surg Res       Date:  1974-03       Impact factor: 2.192

3.  Standardized intracardiac measurements of two-dimensional echocardiography.

Authors:  I Schnittger; E P Gordon; P J Fitzgerald; R L Popp
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

4.  The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy.

Authors:  P M Shah; A G Adelman; E D Wigle; F L Gobel; H B Burchell; T Hardarson; R Curiel; C De La Calzada; C M Oakley; J F Goodwin
Journal:  Circ Res       Date:  1974-08       Impact factor: 17.367

5.  M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction.

Authors:  Y L Doi; W J McKenna; J Gehrke; C M Oakley; J F Goodwin
Journal:  Am J Cardiol       Date:  1980-01       Impact factor: 2.778

6.  Angina in idiopathic hypertrophic subaortic stenosis. A clinical correlate of regional left ventricular dysfunction: a videometric and echocardiographic study.

Authors:  M G Sutton; A J Tajik; H C Smith; E L Ritman
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

7.  Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries.

Authors:  B J Maron; S E Epstein; W C Roberts
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

8.  Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  F J ten Cate; J Roelandt
Journal:  Am Heart J       Date:  1979-06       Impact factor: 4.749

9.  Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy.

Authors:  M Funakoshi; M Imamura; J Sasaki; M Fujino; T Kawano; Y Sasaki; Y Nakashima; T Motooka; K Fukuda; M Imagawa
Journal:  Jpn Heart J       Date:  1984-09

10.  [Congestive, hypertropic cardiomyopathy--intermediary form of primary myocardial disease? (author's transl)].

Authors:  O M Hess; J Schneider; H O Gloor; U M Lütolf; G Keiser
Journal:  Z Kardiol       Date:  1977-02
View more
  5 in total

1.  Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy.

Authors:  Hirotaka Kimura; Satoshi Eguchi; Junko Sasaki; Keiji Kuba; Hiroki Nakanishi; Shunsuke Takasuga; Masakazu Yamazaki; Akiteru Goto; Hiroyuki Watanabe; Hiroshi Itoh; Yumiko Imai; Akira Suzuki; Noboru Mizushima; Takehiko Sasaki
Journal:  JCI Insight       Date:  2017-01-12

2.  Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) in patients with coexistent hypertrophic cardiomyopathy and coronary spastic angina.

Authors:  Akiyoshi Ogimoto; Yuji Shigematsu; Jun Nakura; Yuji Hara; Tomoaki Ohtsuka; Katsuhiko Kohara; Mareomi Hamada; Tetsuro Miki; Jitsuo Higaki
Journal:  J Mol Med (Berl)       Date:  2005-03-19       Impact factor: 4.599

3.  Compensated hypertrophy of cardiac ventricles in aged transgenic FVB/N mice overexpressing calsequestrin.

Authors:  Yoji Sato; Albrecht G Schmidt; Helen Kiriazis; Brian D Hoit; Evangelia G Kranias
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

4.  Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction.

Authors:  Nobuichiro Yagi; Osamu Seguchi; Hiroki Mochizuki; Kensuke Kuroda; Seiko Nakajima; Takuya Watanabe; Masanobu Yanase; Naoki Tadokoro; Satsuki Fukushima; Tomoyuki Fujita; Norihide Fukushima
Journal:  ESC Heart Fail       Date:  2021-10-27

5.  Echocardiographic Predictors of All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy following Pacemaker Implantation.

Authors:  Nixiao Zhang; Wei Hua; Xiaoping Li; Yiran Hu; Hongxia Niu; Chi Cai; Min Gu; Xuhua Chen; Shu Zhang
Journal:  Cardiol Res Pract       Date:  2020-02-14       Impact factor: 1.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.